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Background: This study was aimed to investigate the diagnostic value of fiberoptic bronchoscopy (FOB) with chest
high-resolution computed tomography (HRCT) for the rapid diagnosis of active pulmonary tuberculosis (PTB) in
patients suspected of PTB but found to have a negative sputum acid-fast bacilli (AFB) smear.
Methods: We evaluated the diagnostic accuracy of results from FOB and HRCT in 126 patients at Gangnam
Severance Hospital (Seoul, Korea) who were suspected of having PTB.
Results: Of 126 patients who had negative sputum AFB smears but were suspected of having PTB, 54 patients
were confirmed as having active PTB. Hemoptysis was negatively correlated with active PTB. Tree-in-bud
appearance on HRCT was significantly associated with active PTB. The sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) of FOB alone was 75.9%, 97.2%, 95.3%, and 84.3%, respectively, for the
rapid diagnosis of active PTB. The combination of FOB and HRCT improved the sensitivity to 96.3% and the NPV to
96.2%.
Conclusions: FOB is a useful tool in the rapid diagnosis of active PTB with a high sensitivity, specificity, PPV and
NPV in sputum smear-negative PTB-suspected patients. HRCT improves the sensitivity of FOB when used in
combination with FOB in sputum smear-negative patients suspected of having PTB.Background
Tuberculosis (TB) is a major health problem around the
world, with an approximate incidence of 9.4 million
(8.9–9.9 million) and with about 1.7 million TB-related
deaths in 2009 [1,2]. The global strategy to control TB is
prompt diagnosis, notification, and successful treatment
of patients with active, transmissible disease. Early diag-
nosis of active pulmonary tuberculosis (PTB) is critical
for TB control.
Unfortunately, diagnosis of active PTB is often delayed
because fewer than half of these patients have a positive
sputum smear (29–39% in 2009 in Korea) [1,3], and isola-
tion of Mycobacterium tuberculosis (MTB) takes a long
time. Acid-fast bacilli (AFB) smears of respiratory speci-
mens (at least two or more specimens) are important for
the prompt diagnosis of PTB, but AFB smears have poor
sensitivity (30–70%) despite high specificity (98–99%).* Correspondence: littmann@yuhs.ac
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(80–85%), but culture results usually require 3–8 weeks [4].
The diagnosis of TB and the decision to start treatment
against sputum smear-negative TB is usually dependent on
clinical features, but 20% of PTB patients are completely
asymptomatic whereas 42–86% of PTB patients may be
symptomatic. Sputum smear-negative PTB patients are es-
pecially likely to show no or mild respiratory symptoms
and systemic manifestations [5].
Chest x-ray is another method often used in PTB
screening, but in sputum smear-negative TB, many cases
showed atypical x-ray patterns or normal findings [6]. In
addition, this method has the limitation of a high false
positive rate due to previous PTB infection in an inter-
mediate or high TB burden country. To assist in the
diagnosis of sputum smear-negative PTB and latent TB
infection (LTBI), clinicians use the tuberculin skin test
(TST). However, the TST is limited in application due to
cross-reactivity with non-tuberculous mycobacteria
(NTM) species and Bacillus Calmette-Geurin (BCG)
vaccine strains, and its sensitivity is affected by both
malnutrition and immunosuppression [7].an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Shin et al. BMC Infectious Diseases 2012, 12:141 Page 2 of 7
http://www.biomedcentral.com/1471-2334/12/141Chest high-resolution computed tomography (HRCT)
provides information about the extent and distribution
of PTB and can be a great help in identifying its activity.
In sputum smear-negative cases, HRCT is superior to
chest x-ray in the diagnosis of PTB and in the determin-
ation of its extent and distribution. Further, it confirms
the presumptive diagnosis of active PTB and allows anti-
tuberculosis treatment to commence more quickly. Des-
pite some disadvantages such as high cost and radiation
exposure, HRCT is widely used when traditional meth-
ods have failed to diagnose PTB in sputum smear-
negative patients. Typical radiological patterns of PTB
reactivation such as upper lobe involvement or cavity
formation are rarely observed in sputum smear-negative
cases due to the smaller burden of mycobacterium [5];
therefore, HRCT alone is limited in diagnosing PTB in
sputum smear-negative patients.
Fiberoptic bronchoscopy (FOB) can provide alternative
respiratory specimens for diagnosis [8,9], especially from
specific sites that are suspected by radiological testing
for involvement of PTB when sputum expectoration has
repeatedly failed because sputum is absent [10]. FOB is
also more useful in the diagnosis of endobronchial TB,
which can be seen as normal in HRCT, and FOB may be
superior in the differential diagnosis of tuberculosis with
other commonly encountered diseases such as pneumo-
nia or lung cancer [11]. Despite the fact that it is more
aggressive and relatively expensive, FOB is considered
useful for the diagnosis of sputum smear-negative PTB
because of these advantages. Results of bronchial wash-
ing specimens with AFB smears or MTB polymerase
chain reaction (PCR) and tissue specimens from
bronchoscopic or transbronchial biopsies are usually
received within one week, thus enabling rapid diagnosis
before the availability of confirmation from sputum cul-
tures of sputum smear-negative PTB patients.
The aim of this study was to evaluate the diagnostic
value of FOB with HRCT in the diagnosis of active PTB
in patients suspected of PTB but presenting with a nega-
tive sputum smear in an intermediate TB burden
country.
Methods
Study setting and subjects
We retrospectively reviewed the clinical records and
FOB and HRCT results of all patients with suspected
PTB who visited the pulmonary clinic of Gangnam
Severance Hospital, Seoul, Korea from January 2009 to
December 2010.
Inclusion criteria were (1) age of at least 18 years with
clinical or radiographic suspicion of active PTB, (2)
negative AFB smear results of 2 or more sputum pairs
or failure to expectorate sputum (in other words, could
not expectorate sputum voluntarily, did not submit anysputum specimen) and (3) having received both FOB
and HRCT within 1 month due to suspected PTB before
initiation of anti-TB treatment. When FOB was per-
formed, a bronchial washing from the affected lung was
acquired for AFB smear, mycobacterial culture and
MTB-PCR for all patients. A bronchoscopic biopsy was
performed on patients with an endobronchial lesion.
Exclusion criteria were (1) AFB smear-positive patients,
(2) patients with clinically diagnosed PTB according to
clinical and radiological tuberculosis findings who
showed no clinical improvement with empirical antibio-
tics but did show clinical and radiological improvement
with anti-tuberculosis medication, and (3) patients with
inconclusive diagnoses due to loss of follow-up.
From January 2009 to December 2010, 182 patients
who were suspected of having PTB visited our clinic and
underwent FOB and chest CT. HRCT was performed
with contrast CT, simultaneously. After excluding
smear-positive PTB patients and patients with other ex-
clusion criteria, we evaluated the diagnostic accuracy of
FOB and HRCT results in 126 patients. The recorded
clinical information on these patients included age, gen-
der, cough, sputum, fever, hemoptysis, chest pain, and
weight loss.
Bronchoscopic procedure is performed according to
our institute’s infection regulation and instruction guide-
line. Inspectors wear N95 masks, goggles and gown dur-
ing procedure, bronchosopy room is equipped with
negative pressure isolation and air disinfection system,
Bronchoscopy is performed according to manufacturer’s
guidelines plus scope surveillance.
Diagnostic definition
Active PTB was confirmed when (1) MTB was cultured
or (2) a caseating granuloma was found in the lung
tissue by bronchoscopic biopsy or transthoracic needle
biopsy, and when the PTB showed appropriate response
to treatment. In cases diagnosed by pathology, active
PTB was confirmed only if MTB tissue culture or tissue
MTB-PCR was positive, for excluding NTM or other
granulomatous diseases. A final diagnosis of ‘non-TB’
was accepted when an alternative diagnosis was reached.
A rapid diagnosis of sputum smear-negative PTB by
FOB was defined as a diagnosis of PTB through methods
that yielded results within 1 week: (1) a positive AFB
smear, (2) positive MTB-PCR, or (3) a caseating granu-
loma upon biopsy.
CT findings were reviewed by two experienced thor-
acic radiologists, without clinical information or final
diagnosis in each case. CT findings were described as
having more than one of the following characteristics:
(1) consolidation, (2) cavities, (3) centrilobular air space
nodules, (4) tree-in-bud appearance and (5) hilar and/or
mediastinal lymph node enlargement. After reviewing
Figure 1 Study flowchart. Definition of abbreviations: FOB = fiberoptic
bronchoscopy, CT = computed tomography, N = number, TB =
tuberculosis.
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discussed and reached a final diagnosis by consensus.
The definition of an immunocompromised condition
included the following: (1) having a diagnosis of diabetesmel-
litus, (2) undergoing chemotherapy for an underlying malig-
nancy at the time of TST and QuantiFERONW-TB Gold In-
Tube (QFT-IT, Cellestis Ltd; Carnegie, Australia) testing, (3)
having had received either a solid organ transplant or bone
marrow transplant, (4) having a diagnosis of end-stage renal
disease and on renal replacement therapy, (5) having a diag-
nosis of advanced liver cirrhosis with Child-Pugh class C, (6)
being seropositive for human immunodeficiency virus, or (7)
undergoing daily administration of systemic corticosteroids
(at least 15mg prednisone per day formore than 1month) or
combination therapy with low dose corticosteroids and other
immunosuppressants including azathioprine, mycopheno-
late, methotrexate, cyclosporine, or cyclophosphamide.
For the combination of FOB and HRCT, the results of
the combination were considered positive when at least
one test was positive.
Analysis
Data were analyzed with SPSS statistical software (version
18.0; SPSS; Chicago, IL, USA). Univariate comparisons be-
tween active PTB and non-TB patients were performed
using Fisher’s exact test for categorical variables and the
Mann–Whitney test for continuous variables, where ap-
propriate. Associations of clinical and radiological para-
meters with active PTB diagnosis were analyzed using
univariate or multivariate logistic regression modeling. For
multivariate analysis, variables were incorporated into the
model in a stepwise manner. All tests of significance were
two-sided and a P value< 0.05 was considered statistically
significant. Odds ratios (ORs) and 95% confidence inter-
vals (95% CIs) were calculated. Sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value
(NPV) for the diagnosis of active PTB disease were calcu-
lated for each diagnostic test.
Ethical issues
This study was approved by the Institutional Review
Board of the Gangnam Severance Hospital, Yonsei
University College of Medicine (IRB No: 3-2011-0118).
Results
Demographic characteristics
Of the 145 patients with suspected sputum smear-
negative TB, five patients were excluded due to clinically
diagnosed PTB, and 14 patients were excluded due to
inconclusive diagnoses (Figure 1).
Baseline characteristics of the non-excluded 126
patients are summarized in Table 1. Active PTB was
diagnosed in 54 patients (42.9%), of which 48 (88.9%)
had positive TB cultures and 6 (11.1%) cases wereconfirmed by pathology and MTB-PCR. Of 48 culture-
confirmed cases, 28 were culture positive by both spu-
tum and bronchial washing specimens, 6 by sputum
only, and 14 by bronchial washing specimens only.
Alternative (non-TB) diagnoses were made for 72
patients (34 pneumonia, 5 NTM colonization, 15 seque-
lae of a previous TB infection, 12 lung cancers, and 6
interstitial lung disease).
The mean patient age was 51.0 ± 18.2 years, and the
mean age of the non-TB group was higher than that of
the TB group (55.4 ± 16.6 years vs. 45.3 ± 18.8 years, re-
spectively, P = 0.002). Immunocompromised conditions
were found in 11 patients (6 diabetes, 2 chemotherapy, 2
hematologic malignancies, and 1 systemic corticosteroid
use). There was no difference between the TB and non-
TB groups in terms of immunocompromised status, but
previous TB history was significantly different between
the TB and non-TB groups (P = 0.014, Table 1).
Clinical characteristics and HRCT findings in sputum
smear-negative TB suspects
Chest x-rays showed a higher positive rate in the TB
group than in the non-TB group (53.7% vs. 20.8%, re-
spectively, P< 0.001), and QFT-IT also showed signifi-
cantly higher positive rate in the TB group than in the
non-TB group (87.0% vs. 46.4%, respectively, P = 0.009)
(Table 1). Only hemoptysis (P = 0.009, OR= 0.30 [0.12–
0.76, 95% CI]) was negatively correlated with active PTB
in sputum smear-negative suspects (Table 2).
Fifty-three patients were suspected of having active
PTB by HRCT, and 38 (71.7%) were correctly diagnosed
with active PTB. Of the 73 patients suspected to be non-
Table 1 Demographic and clinical characteristics of all sputum smear-negative TB suspects
Characteristic All suspects TB Non-TB P-value
N=126 N=54 N=72
Age, years (mean± SD) 51.0 ± 18.2 45.3 ± 18.8 55.4 ± 16.6 0.002
Male, n (%) 68 (54.0) 26 (48.1) 42 (58.3) 0.256
Previous TB history, n (%) 33 (26.2) 8 (14.8) 25 (34.7) 0.014
Immunocompromised patient, n (%) 11 (8.7) 4 (7.4) 7 (9.7) 0.649
CXR positivity, n (%) 44 (34.9) 29 (53.7) 15 (20.8) < 0.001
QFT-IT positivity*, n (%) 33/51 (64.7) 20/23 (87.0) 13/28 (46.4) 0.009
Active pulmonary TB, n (%) 54 (42.9) 54 (100.0)
Culture confirmed, n (%)† 48 (88.9)
Biopsy confirmed, n (%) 6 (11.1)
Definition of abbreviations: TB= tuberculosis, SD= standard deviation, n=number, CXR= chest x-ray, QFT-IT=QuantiFERONW-TB Gold In-Tube.
*51 of 126 cases were examined with this test.
†Of the 48 culture-confirmed cases, 28 showed cultures positive in both sputum and bronchial washing specimens, 6 only in sputum and 14 only in bronchial
washing specimens.
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in the diagnosis of PTB showed a significant difference
between TB and non-TB patients (P< 0.001) (data not
shown). The most frequently observed CT findings
(in order of decreasing frequency) were consolidation,
mediastinal lymphadenopathy, tree-in-bud appearance,
and nodules. Tree-in-bud nappearance was the only sig-
nificant finding associated with active PTB status
(P< 0.001, OR= 5.10 [2.37–10.99, 95% CI]) (Table 3).
Bronchoscopic characteristics in PTB patients
Of the 54 patients confirmed with active PTB, 41
patients had TB and 13 patients did not have TB accord-
ing to rapid diagnosis via bronchoscopic methods. As a
result, two non-TB patients were misdiagnosed as having
TB by bronchoscopic rapid diagnosis (Additional file 1:
Table S1). Baseline characteristics were not different be-
tween TB and non-TB patients divided by broncho-
scopic diagnosis (Additional file 1: Table S2).
The bronchoscopic findings are summarized in Table 4.
Of the 54 PTB-confirmed patients, 42 patients hadTable 2 First presenting symptoms of patients with sputum s
Symptoms All suspects TB
N=126 N=54
Cough, n (%) 70 (55.6) 34 (63.0)
Sputum, n (%) 42 (33.3) 18 (33.3)
Fever, n (%) 27 (21.4) 13 (24.1)
Hemoptysis, n (%) 31 (24.6) 7 (13.0)
Chest wall pain, n (%) 22 (17.5) 13 (24.1)
Weight loss, n (%) 4 (3.2) 3 (5.6)
Definition of abbreviations: TB= tuberculosis, n=number, OR=odds ratio, 95% CI= 9positive bronchial washing cultures (Table 4), 34 patients
had positive sputum cultures, and 28 patients showed a
positive result on both the sputum and bronchial wash-
ing cultures, but 14 patients had positive only in bron-
chial washing cultures (Additional file 1: Table S3).
Of the 54 PTB-confirmed patients, 41 (75.9%) patients
were rapidly diagnosed in less than 1 week by bronchial
washing AFB smear, MTB-PCR and/or biopsy, and 13
patients were confirmed several weeks later by bronchial
washing or sputum culture results. AFB smears produced
by bronchial washing showed positive results for 25.9%
(14/54) of the PTB-confirmed patients, and bronchoscopic
biopsy results were positive in 22 of 23 patients who
underwent a biopsy (Table 4). Of 23 patients who under-
went a biopsy, a transbronchial biopsy was performed in 5
patients and a bronchial biopsy was performed in 18
patients with an endobronchial lesion (data not shown).
MTB-PCR from a bronchial washing showed positive
results in 61.1% (33/54) of patients (Table 4), and 2 of the
finally diagnosed 72 non-TB patients showed false-
positive results (Additional file 1: Table S1).mear-negative TB
Non-TB P-value OR (95% CI)
N= 72
36 (50.0) 0.147 1.70 (0.827–3.493)
24 (33.3) 1.000 1.00 (0.473–2.114)
14 (19.4) 0.531 1.31 (0.559–3.087)
24 (33.3) 0.009 0.30 (0.117–0.757)
9 (12.5) 0.090 2.22 (0.870–5.662)
1 (1.4) 0.313 4.18 (0.422–41.308)
5% confidence interval.
Table 3 Multivariate regression analysis of CT findings in sputum smear-negative TB suspects
Characteristic All suspects TB Non-TB P-value OR (95% CI)
N = 126 N=54 N=72
Consolidation, n (%) 88 (69.8) 38 (70.4) 50 (69.4) 0.726 1.05 (0.484–2.257)
Nodule, n (%) 50 (39.7) 23 (42.6) 27 (37.5) 0.435 1.24 (0.602–2.541)
Cavity, n (%) 23 (18.3) 15 (27.8) 8 (11.1) 0.050 3.08 (1.195–7.924)
Tree-in-bud, n (%) 52 (41.3) 34 (63.0) 18 (25.0) <0.001 5.10 (2.366–10.991)
Mediastinal LAP, n (%) 53 (42.1) 26 (48.1) 27 (37.5) 0.940 1.55 (0.756–3.167)
Definition of abbreviations: CT= computed tomography, TB= tuberculosis, n=number, OR=odds ratio, 95% CI= 95% confidence interval, LAP= lymphadenopathy.
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negative TB suspects
The diagnostic accuracy of FOB, HRCT, and the com-
bination of FOB and HRCT in sputum smear-negative
TB suspects is summarized in Table 5. The sensitivity of
FOB in the rapid diagnosis of active PTB was 75.9%
(95% CI, 69.0–78.6%), and the specificity was 97.2%
(95% CI, 92.0–99.2%). The sensitivity of HRCT in the
diagnosis of active PTB was 85.2% (95% CI, 75.2–92.3%),
and the specificity was 72.2% (95% CI, 64.7–77.6%). The
PPV of FOB was 95.3% (95% CI, 86.7–98.7%) and the
NPV of FOB was 84.3% (95% CI, 79.8–86.1%) in the
rapid diagnosis of active PTB. These values were higher
than the PPV of HRCT (69.7% [95% CI, 61.5–75.5%])
and similar to the NPV of HRCT (86.7% [95% CI, 77.7–
93.1%]). The combination of FOB and HRCT improved
the sensitivity to 96.3% and the NPV to 96.2%.
Discussion
In this retrospective study, we found that FOB showed high
sensitivity, specificity, PPV, and NPV in the rapid diagnosis
of sputum smear-negative PTB, and the combination of
FOB and HRCT increased the sensitivity and NPV.
Several previous studies evaluated clinical characteris-
tics and scoring systems for the diagnosis of sputum
smear-negative PTB [12-14]. Samb et al. [12] reported
independent predictors of active PTB including a
chronic cough lasting longer than 3 weeks, chest pains
longer than 15 days, absence of sputum, and absence ofTable 4 Bronchoscopic findings in 54 patients confirmed to h
Bronchial washing culture
Bronchial washing AFB smear
Bronchial washing MTB-PCR
Bronchoscopic biopsy (TBB + bronchial biopsy)
Bronchial washing AFB smear +MTB-PCR+ bronchoscopic biopsy
Definition of abbreviations: PTB= pulmonary tuberculosis, TB= tuberculosis, AFB= aci
reaction, TBB= transbronchial lung biopsy.
*Numbers of patients with positive results in each test/total numbers of patients whdyspnea, and Lee et al. [14] reported that the lack of
sputum was a positive predictor of active PTB. But even
in these studies, the specificity of the clinical predictors
or scoring system was low, and the PPV was reported at
a mere 50%. In our study, hemoptysis was the only nega-
tive predictor in sputum smear-negative TB suspects,
and other clinical characteristics did not help in the pre-
diction of active PTB.
We discovered that tree-in-bud appearance was a
meaningful HRCT finding in the diagnosis of sputum
smear-negative PTB. Recently, several studies have
reported that tree-in-bud appearance, lobular consolida-
tion and large nodules were positively associated with
active PTB in sputum smear-negative TB suspects, but
the diagnostic accuracy was not satisfactory [14,15].
Matsuoka et al. [16] stated that CT findings in sputum
smear-negative patients differed from those in smear-
positive patients and suggested that CT findings are not
helpful in judging sputum smear-negative TB suspects.
Despite being less infectious than sputum smear-positive
PTB, smear-negative PTB serves as an important cause of
transmission in communities by delaying diagnosis and
precluding initiation of treatment and often leads to com-
plications of irreversible lung damage in infected indivi-
duals [4]. Therefore, sputum smear-negative PTB often
requires more invasive diagnostic tools to be distinguished
from other diseases such as lung cancer. In addition, in
intermediate or high TB burden countries such as South
Korea, beginning unnecessary anti-TB treatment prior toave active PTB
TB Culture confirmed Biopsy confirmed
N=54 N=48 N=6
42/54 (77.8) 42/48 (87.5) 0/6 (0.0)
14/54 (25.9) 12/48 (25.0) 2/6 (33.3)
33/54 (61.1) 32/48 (66.7) 1/6 (16.7)
22/23 (95.7) 16/17 (94.1) 6/6 (100.0)
41/54 (75.9) 35/48 (72.9) 6/6 (100.0)
d-fast bacilli, MTB=mycobacterial tuberculosis, PCR=polymerase chain.
o underwent each test (%).
Table 5 Diagnostic accuracy in all sputum smear-negative TB suspects
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) +LR (95% CI) −LR (95% CI)
FOB 0.759 (0.690–0.786) 0.972 (0.920–0.992) 0.953 (0.867–0.987) 0.843 (0.798–0.861) 27.333 (8.674–99.257) 0.248 (0.216–0.337)
CT 0.852 (0.752–0.923) 0.722 (0.647–0.776) 0.697 (0.615–0.755) 0.867 (0.777–0.931) 3.067 (2.131–4.117) 0.205 (0.099–0.383)
FOB+CT 0.963 (0.879–0.993) 0.708 (0.645–0.731) 0.712 (0.650–0.735) 0.962 (0.876–0.993) 3.302 (2.477–3.696) 0.052 (0.009–0.188)
Definition of abbreviations: TB= tuberculosis, PPV=positive predictive value, NPV=negative predictive value, +LR=positive likelihood ratio, -LR=negative likelihood
ratio, 95% CI= 95% confidence interval, FOB= fiberoptic bronchoscopy, CT= computed tomography.
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necessary economic burden to the community and drug
side effects to the patient.
Lee et al. [14] reported that the sensitivity and the speci-
ficity of sputum TB-PCR was 43.2% (95% CI, 27–60%)
and 97.7% (95% CI, 86–99%), respectively. Because of its
low sensitivity and NPV (66.7% [95% CI, 54–78%]), spu-
tum TB-PCR alone was limited in ruling out TB. In a re-
cent meta-analysis study [17], the sensitivity and the
specificity of QFT-IT was 80% (95% CI, 75–84%) and 79%
(95% CI, 78–84%), respectively, and the sensitivity and the
specificity of T-SPOT TB was 81% (95% CI, 78–84%) and
59% (95% CI, 56–62%), respectively. The diagnostic sensi-
tivity of both interferon-gamma release assays (IGRAs)
was higher than that of the TST, but the sensitivity of
IGRAs was still not high enough for IGRAs to be used as
a rule out test for TB. In addition, the specificity of the
IGRAs was not sufficient for the diagnosis of active TB
disease with differentiation from latent TB infection.
In previous studies, FOB had a sensitivity of 80–93% and
a specificity of 70–95% [8,9,18,19] for rapid diagnosis of
sputum smear-negative PTB, and HRCT had a sensitivity
of 60–80% and a specificity of 50–70% [14, 20,21]. Our
results indicate that HRCT has a similar sensitivity of 85.2%
and specificity of 72.2%, but HRCT alone is limited as usual
in the diagnosis of PTB in sputum smear-negative TB sus-
pects due to its low PPV of 69.7% (positive likelihood ratio
(LR+), 3.067 [95% CI, 2.131–4.117]). We found that FOB
alone is useful for the rapid diagnosis of sputum smear-
negative PTB with a high PPV of 95.3% (LR+= 27.333
[95% CI, 8.674–99.257]). FOB is also useful for the exclu-
sion of non-TB cases from patients suspected of having ac-
tive PTB with a high specificity and NPV in our setting.
The combination of FOB with HRCT increased the sensi-
tivity to 96.3% and NPV to 96.2%.
The high cost and concerns about the invasiveness of
FOB and radiation exposure of HRCT limit the useful-
ness of these tests, but FOB is a safe and widely per-
formed procedure. Previous studies [22,23] have
reported that with the help of oxygenation, adequate
premedication, and performance by experienced physi-
cians, FOB shows very low complication rates and few
life-threatening side effects. One previous study investi-
gating the cost-effectiveness of FOB and HRCT in the
diagnosis of PTB [21] reported that FOB and HRCT playsignificant roles in the moderate or high PTB probability
setting compared with the low PTB probability setting.
Considering the high specificity of our study, FOB and/
or HRCT would be useful in a high TB burden country
as well as in an intermediate TB burden country such as
South Korea.
There are several limitations in this study. First, it was
a retrospective study and the study population and clin-
ical setting were selective and limited, so it is difficult to
generalize this result to other settings. Second, the com-
monly used TST was not evaluated in our study. This
was based on previous studies showing the limitation of
TST for evaluating TB in South Korea due to BCG vac-
cination [24,25]. Third, the use of FOB in the diagnosis
of PTB is not clinically available worldwide. To improve
diagnostic accuracy and ensure safety, a well-trained pul-
monologist is essential. High cost and the complication
risk limit the use of FOB in other situations. However,
our study demonstrates that FOB and FOB with HRCT
can play an important role in the rapid diagnosis of active
PTB in sputum smear-negative patients suspected of TB.
Conclusions
In conclusion, our results suggest that FOB has good sensi-
tivity, specificity, PPV, and NPV and was useful in the rapid
diagnosis of sputum smear-negative PTB and the exclusion
of non-TB in sputum smear-negative TB-suspected
patients. HRCTalone was limited for the diagnosis of active
PTB, but the combination of FOB and HRCT may improve
the sensitivity of FOB in the rapid diagnosis of sputum
smear-negative PTB. Based on our results, we suggest that
physicians actively consider performing FOB and HRCT in
sputum smear-negative patients suspected of TB.
Additional file
Additional file 1: Tables S1-S3. Bronchoscopic findings of all subjects.
Tables S2. Diagnostic and clinical characteristics of active PTB confirmed
54 patients according to bronchoscopic diagnosis. Tables S3.
Bronchoscopic findings in 54 active PTB patients according to sputum
mycobacteria culture results.
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